THRB and Hypercholesterolemia: Liver and TRβ-selective agonist VK2809 also showed positive results from a Phase 2 trial in patients with hypercholesterolemia and NAFLD, and is currently being evaluated in a Phase 2b clinical trial in patients with biopsy-confirmed NASH.